Protocol

Immunocine Dendritic Cell Vaccine Protocol

Curated from
Matt Halpert

Personalized double-loaded dendritic cell vaccine therapy pathway, including tissue preservation, patient preparation (reduced systemic inflammation, appropriate timing), and administration via image-guided injection near draining lymph nodes.

6 items drawn from 1 source ▲ Strong endorse

Assembled by Cited from Matt Halpert's recorded recommendations across multiple sources. It is not an ordered program and was not created or endorsed by them — it's our grouping of what they've said on the record.

Components

6

How this protocol has evolved

Protocol evolved from ~2011-2012 lab discovery of the 'double-loading' MHC Class I + Class II mechanism, through FDA-fast-tracked trials (glioblastoma, pancreatic ductal adenocarcinoma, refractory melanoma) in the US, and parallel Immunocine clinics in Cancun and Cabo for patients outside trial criteria. Immunocine Preserve was added as a safeguard service so tissue would be available if conventional therapy succeeded initially but cancer later relapsed.

Sources

1